Adherence and persistence with istradefylline treatment in patients with Parkinson’s disease in the United States
Patients initiating istradefylline at 40 mg <i>versus</i> 20 mg and those with Medicare Advantage <i>versus</i> commercial insurance were more likely to have higher adherence and longer persistence with istradefylline.
Authors
- Michael J. Soileau (ORCID: https://orcid.org/0000-0002-3944-1327)
- Shivendra G. Tewari (ORCID: https://orcid.org/0000-0003-0310-0915)
- Reversa Joseph
- Yen‐Hua Chen (ORCID: https://orcid.org/0000-0002-5794-3769)
- Joyce Qian
- Hannah Cummings
Institutions
- Morristown Medical Center (US)
- Society for Ambulatory Anesthesia (US)
- Texas Dermatology and Laser Specialists (US)
- LEK Consulting (United States) (US)
- Kyowa Kirin (France) (FR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fphar.2025.1548631
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kyowa Hakko Kirin